Tirzepatide
Metabolic & Weight ManagementDual GIP/GLP-1 receptor agonist offering superior weight loss compared to semaglutide, marketed as Mounjaro and Zepbound.
Key Benefits
- ✓Superior weight loss (20-24%)
- ✓Enhanced insulin sensitivity
- ✓Improved lipid profiles
- ✓Better glycemic control
- ✓Reduced cardiovascular risk factors
- ✓Preserved lean muscle mass
Dosing Information
Detailed Protocol
Administered via subcutaneous injection once weekly. Gradual titration starting at 2.5mg and increasing every 4 weeks as tolerated. Maximum dose is 15mg weekly.
About Tirzepatide
Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist. This dual action provides even greater weight loss than GLP-1 agonists alone, with clinical trials showing 20-24% weight reduction. It improves insulin sensitivity, reduces appetite, and has favorable metabolic effects.
Research Notes
The SURMOUNT clinical trial program demonstrated superior weight loss compared to semaglutide. FDA approved for type 2 diabetes (Mounjaro) in 2022 and obesity (Zepbound) in 2023.
Potential Side Effects
- •Nausea and vomiting
- •Diarrhea
- •Decreased appetite
- •Constipation
- •Indigestion
- •Injection site reactions
Always consult with a healthcare professional before starting any peptide therapy.